Day: October 29, 2025

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) — Dynamix Corporation III (the “Company”) announced the pricing of its initial public offering of 17,500,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “DNMXU” commencing October 30, 2025. Each unit consists of one Class A ordinary share of the Company and one-half of one warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share of the Company at an exercise price of $11.50 per share. Once the securities constituting the units begin separate trading, the Company expects that the Class A ordinary shares and warrants will be listed on Nasdaq under the symbols “DNMX” and “DNMXW,” respectively. The initial public offering is expected to close on Friday, October 31, 2025, subject to customary...

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) — National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) (“NHP”) announced today that it will release its financial results for the third quarter ended September 30, 2025 on Wednesday, November 5, 2025 after market close. NHP’s executive leadership will host a webcast on Thursday, November 6, 2025, beginning at 1:00 p.m. ET, to review the third quarter results. Please click here to join the webcast at 1:00 p.m. ET on November 6, 2025 – pre-registration is not required. The webcast will be available at exactly the start time above and cannot be joined earlier. A replay of the webcast will be posted on NHP’s website. About National Healthcare Properties, Inc. National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) is a publicly registered real estate investment trust focused on...

Results include Cygnus’ first hole at Cedar Bay which returned a wide interval of 10.6m at 4.1g/t AuEq, including high-grade gold up to 29.1g/t AuEq Chibougamau Copper-Gold Project, Canada HIGHLIGHTS:First hole at the Cedar Bay prospect within the Chibougamau Project returns up to 29.1g/t AuEq over 0.4m within a wide interval of:10.6m at 4.1g/t AuEq (3.6g/t Au, 0.3% Cu & 2.8g/t Ag) (CDR-25-11W1)Including 2.9m @ 6.7g/t AuEq (6.2g/t Au, 0.3% Cu & 6.3g/t Ag)This intersection is 200m outside the recently released Mineral Resource, which is based on drilling before Cygnus took ownership of the Chibougamau Project   Cedar Bay has a high-grade gold-dominant Resource containing 67koz at 8.1g/t AuEq (M&I) and 205koz at 7.8g/t AuEq (Inferred) with significant potential for growth At the Corner Bay deposit, the flagship...

Trading of the Company’s shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC Markets and continue clinical operations SOUTH SAN FRANCISCO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company developing novel T cell therapeutics that incorporate phagocytic mechanisms, today announced the receipt of the determination of the Nasdaq Hearings Panel (the “Panel”) to deny the Company’s request to continue the listing of its shares of common stock on Nasdaq. As previously disclosed, the Company has not been in compliance with the requirement set forth in Nasdaq Listing Rule 5550(b)(1) to maintain stockholders’...

Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American Depositary Shares (“ADSs”), for total gross proceeds to the Company of approximately $30 million, before deducting sales agent commissions and offering expenses payable by the Company, to Artisan Partners Limited Partnership (“Artisan”) through Citizens Capital Markets, acting as sales agent. Each ADS represents the right...

NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines’ strong clinical and commercialization expertise in Greater China and other Asian markets NovaBridge also named Mr. Ian Woo, President and Chief Financial Officer of Everest Medicines, to its Board of Directors, bringing substantial expertise in international biopharma finance, operations and management VIS-101 is a novel bifunctional biologic targeting VEGF-A/ANG2, with potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD, DME and RVO. The program is completing a Phase 2 study in China and is expected to be Phase-3-ready in 2026ROCKVILLE, Md., Oct. 29, 2025 (GLOBE NEWSWIRE)...

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES SASKATOON, Saskatchewan, Oct. 29, 2025 (GLOBE NEWSWIRE) — GFG Resources Inc. (TSXV: GFG) (OTCQB: GFGSF) (“GFG” or the “Company”) announces that it has increased its previously announced private placement of premium flow-through units (“Premium Units”) and flow-through shares (“FT Shares”) to raise gross proceeds of up to C$4.23 million (the “Offering”). The Offering will consist of the issuance of up to 11,880,188 Premium Units at a price of C$0.2224 per Premium Unit and up to 8,550,129 FT Shares of the Company at a price of C$0.185 per FT Share, in any combination to maximum aggregate gross proceeds of up to C$4.23 million. Each Premium Unit shall consist of one common share of the Company and one-half of one share purchase warrant, with each whole share purchase...

SAN DIEGO, CA, Oct. 29, 2025 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”) today announced that it has rescheduled its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”), previously scheduled to be held at 4:00 PM (Pacific Time) on Thursday, October 30, 2025, to a new date of Monday, December 15, 2025. The Company intends to set a record date for a determination of stockholders entitled to notice and to vote at the 2025 Annual Meeting of October 31, 2025. The new record date allows a significant number of new shareholders to participate, following the September 30, 2025 announcement of the Company’s signing of a definitive agreement to merge with privately held RTB Digital, Inc. (“Roundtable”). Roundtable is a Web3 digital media SaaS technology company (see recent related...

CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.  Mr. Cusack has more than 20 years of experience in investment management and corporate finance.  Most recently, from 2011 to 2025, he served as a Managing Director of Starboard Value LP, a New York-based investment fund with approximately...

Presentation scheduled for 4:30 p.m. ET NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a technology-enabled financial services platform modernizing trading, clearing, settlement, and banking, today announced that it will present at the ThinkEquity Conference being held at the Mandarin Oriental, New York on Thursday, October 30, 2025, at 4:30 p.m. Eastern Time. John Schaible, Executive Chairman of AtlasClear Holdings, and Craig Ridenhour, President of AtlasClear Holdings, will deliver the Company’s presentation. They will also be available for one-on-one meetings with investors throughout the conference. To request a meeting, please contact your ThinkEquity representative or the investor relations contacts listed below. A live webcast of the presentation...